




FIG. 1




FIG. 2




FIG. 3

FIG. 4





FIG. 5







FIG. 6



FIGS. 7A-7E



* Conjugation buffer: 20mM Na₃PO₄, 5% w/v BSA, 0.25% v/v Tween20, 10% w/v sucrose

FIGS. 8A-8B

FIG. 9A




FIG. 9B





FIG. 9C



FIGS. 9A-9C

FIG. 10A






FIG. 10B



FIGS. 10A-10B

FIG. 11A





FIG. 11B



FIGS. 11A-11B




FIG. 12

FIG. 13A





FIG. 13B



Day 3 at 25°C

FIGS. 13A-13B

FIG. 14A




FIG. 14B





FIG. 14C



FIGS. 14A-14C

FIG. 15B




FIG. 15A




FIG. 15D





FIG. 15C



FIGS. 15A-15D

FIG. 16A





FIG. 16B



FIGS. 16A-16B




FIG. 17




FIG. 18




FIG. 19





FIG. 20



Membrane type	Expected Rate
FF170HP	1.5 cm/min
HFC18002	1.3 cm/min
HFC13502	1.7 cm/min
HFC09002	2.6 cm/min
HFC12002	2.0 cm/min
HFC07502	3.2 cm/min
FF170HP	neg ctrl




FIG. 21

FIG. 22A




FIG. 22B



FIGS. 22A-22B




FIG. 23




FIG. 24

FIG. 25A

reconstitution of LgTrip + substrate spots: No BSA




FIG. 25B

reconstitution of LgTrip + substrate spots: BSA






FIG. 25C

Summary of Fig 25B



FIGS. 25A-25C



FIGS. 26A-26B




FIG. 27




FIG. 28

FIG. 29A




FIG. 29B





FIG. 29C



FIGS. 29A-29C

FIG. 30A




FIG. 30B





FIG. 30C



FIGS. 30A-30C

FIG. 31A





FIG. 31B



FIGS. 31A-31B

FIG. 32A




FIG. 32B





FIG. 32C



FIGS. 32A-32F

FIG. 32D




FIG. 32E






FIG. 32F



FIGS. 32A-32F



Tablet or lyocake embodiments containing all assay components that can be used in cuvettes, test tubes, bottles, snap test type formats, etc.

FIG. 33




FIG. 34





FIG. 35




FIG. 36




FIG. 37

FIG. 38A





FIG. 38B



FIGS. 38A-38B




FIG. 39

FIG. 40A Paper based assay for Remicade NanoBIT






FIG. 40B




FIGS. 40A-40C

FIG. 40C



FIGS. 40A-40C

FIG. 41A



FIGS. 41A-41C




FIG. 41B





FIG. 41C

FIGS. 41A-41C

FIG. 42A



FIGS. 42A-42E

FIG. 42B





FIG. 42C



FIGS. 42A-42E

FIG. 42D





FIG. 42E



FIGS. 42A-42E




FIG. 43




FIG. 44




FIG. 45

Absolute [furimazine] remaining

FIG. 46A





FIG. 46B



FIGS. 46A-46B




FIG. 47




FIG. 48





FIG. 49



+ IL-6	-IL-6	Pre-equilibrated 90 mins	Added at t = 0
■	□	IL-6 + antibodies + LgTrip	Fz
●	○	IL-6 + antibodies	LgTrip + Fz
▲	△	--	IL-6 + antibodies + LgTrip + Fz

FIGS. 50A-50B

FIG. 51A





FIG. 51B



	Trip
LOD	2.1 pg/ml
LLOQ	4.3 pg/ml
ULOQ	16,200 pg/ml

LOD = blank + 3*SD_{blank}
LLOQ = blank + 10*SD_{blank}
ULOQ = [high] + 10*SD_[hi]
→ Values then interpolated on the standard curve and < 10% CV

FIGS. 51A-51B




FIG. 52A

FIG. 52B

Formulation A - without Fz
Ambient temp storage





FIG. 52C

Formulation B - With Fz
Ambient temp storage



FIGS. 52A-52C

FIG. 53A





FIG. 53B

Stability over time at ambient temps



FIGS. 53A-53B




FIG. 54




FIG. 55

FIG. 56A

Add sample and read





FIG. 56B

Single reagent lyophilized 96-well plate
0.01% BSA in PBS assay buffer



FIGS. 56A-56B

FIG. 57A





FIG. 57B



FIGS. 57A-57B




FIG. 58

FIG. 59A





FIG. 59B



FIGS. 59A-59B

Condition 12 of Lyo Run 4 Day 0
2ng/ml 1H11L19-HT-24GS-SmTp9(521)
40ng/ml 16A11-HT-8GS-VSHB
1uM LgTp, 10uM N113




FIG. 60

FIG. 61A





FIG. 61B



*Diluting samples with general serum diluent (GSD) preferred over PBSA. GSD mitigates non-specific IgG effects
Using N205 as substrate*

FIGS. 61A-61B

FIG. 62A





FIG. 62B



FIGS. 62A-62B

FIG. 63A




FIG. 63B




FIG. 63C





FIG. 63D



FIGS. 63A-63D




FIG. 64

FIG. 65A




FIG. 65B





FIG. 65C



FIGS. 65A-65C

FIG. 66B




FIG. 66A





FIG. 66C



FIGS. 66A-66C

FIG. 67A




FIG. 67B





FIG. 67C



FIGS. 67A-76C




FIG. 68

FIG. 69A




FIG. 69B





FIG. 69C



FIGS. 69A-69C

FIG. 70A





FIG. 70B



FIGS. 70A-70B




FIG. 71





FIG. 72A:
Formulated, split-cakes
Yellow Vial: LgBiT-TNF α and furimazine
White Vial: SmBiT – Protein G

FIG. 72D
Dual-BiT Cake format / remicade detection



FIGS. 72A-72D




FIG. 73




FIG. 74

- 5nM SmTrip9-Protein G
- 20,000 SmTrip10-EGFR expressing cells/well
- 1uM LgTrip
- 1 hour incubation at 37C
- Opti-MEM Assay Buffer
- 10uM final LCS
- *n = 3 independent experiments*




FIG. 75





FIG. 76

FIG. 77A


Remicade Titration (anti-TNF α Model)
10nM components, 1uM LgTrip
90minute 37C Incubation, 10uM LCS



FIGS. 77A-77B

FIG. 77B

NanoTrip-Complete Solution Cake-anti-TNF α system
10ng/ml each SmTrip9 521-Protein G+TNF α -SmTrip10+1 μ M LgTrip 3526
10 μ M N205



FIGS. 77A-77B




FIG. 78

Lane	Sample
1	PP Dual Color Ladder
2	505E Ab ctrl
3	HW-0977 + 505E #2
4	HW-1053 + 505E
5	Promega Ladder
6	5IL6 Ab ctrl
7	5IL6 Ab ctrl
8	HW-1010 only
9	5IL6 + HW-1010 rxn
10	HW-1010 only – post clean
11	5IL6 + HW-1010 rxn – post clean
12	HW-1043 only
13	5IL6 + HW-1043 rxn
14	HW-1043 only – post clean
15	5IL6 + HW-1043 – post clean
16	HW-1052 only
17	5IL6 + HW-1052 rxn
18	HW-1052 only – post clean
19	5IL6 + HW-1052 rxn – post clean
20	HW-1055 only
21	5IL6 + HW-1055 rxn
22	5IL6 + HW-1055 rxn – post clean
23	Promega Ladder
24	5IL6 Ab ctrl
25	HW-0984 only
26	5IL6 +HW-0984 rxn
27	HW-0984 only – post clean
28	5IL6 + HW-0984 rxn – post clean
29	Promega Ladder
30	5IL6 Ab ctrl
31	HW-1042 only
32	5IL6 + HW-1042 rxn
33	HW-1042 only – post clean
34	5IL6 + HW-1042 rxn – post clean
35	Promega Ladder
36	5IL6 Ab ctrl
37	HW-1050 only
38	5IL6 +HW-1050 rxn
39	HW-1050 only – post clean
40	5IL6 + HW-1050 rxn – post clean

FIG. 79A




FIG. 79B





FIG. 79C



FIGS. 79A-79C




FIG. 80

Direct Label
62.5 ng/ml HW-0984 + 7.5 ng/ml HW-1053
1 μ M LgTrip 3546, 10 μ M N205
PBSA




FIG. 81

Direct Label
LgTrip 3546




FIG. 82

Individual Antibody-Conjugate Controls
1 μ M LgTrip 3546
PBSA + 10 μ M N205




FIG. 83




FIG. 84




FIG. 85




FIG. 86

FIG. 87A




FIG. 87B





FIG. 87C



FIGS. 87A-87C